Olema Pharmaceuticals, Inc. OLMA
Set alert
7.07 USD 0.00 0.00%
At close
6.51 -0.56 -7.92%
Pre-market · Nov 3, 6:49 AM ET
6.71 Day range 7.13
6.24 52-week range 36.26
- YTD
- -71.72%
- 1 year
- -16.03%
- Open
- 7.00
- Prev close
- 7.07
- Mkt cap
- 618.61M
- Vol
- 1.12M
- Avg vol
- 1.19M
- EPS
- -2.12
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.71
- High
- 7.13
- Forward P/E
- -4.86
- Beta
- 2.01
- Short ratio
- 7.94
- Inst. own
- 118.48%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 10, 2026
- 50-d avg
- 11.34
- 200-d avg
- 17.51
- 1y target
- 40.70
Analyst view
Consensus: none
Price target (mean) 40.70 +475.7% upside
Now 7.07
- Target (low)
- 23.00
- Target (mean)
- 40.70
- Target (high)
- 62.00
Ratings (0m) 12 11 buy · 1 hold · 0 sell
- Strong buy2
- Buy9
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 12
- 1 month ago 12
- 2 months ago 13
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.56384 | -0.63 – -0.49 | -0.51 | -10.6% | 0 | 0.0% | 9 |
| Next quarter | -0.57906 | -0.69 – -0.47 | -0.49 | -18.2% | 0 | 0.0% | 9 |
| Current year | -2.27 | -2.62 – -1.95 | -1.87 | -21.6% | 0 | 0.0% | 9 |
| Next year | -2.48 | -3.04 – -1.81 | -2.27 | -9.1% | 23.12M | 0.0% | 9 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 13, 2026 | Guggenheim | Maintained | Buy | Buy |
| Mar 27, 2026 | Wolfe Research | Initiated | — | Peer Perform |
| Mar 18, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Mar 18, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Mar 17, 2026 | Citigroup | Maintained | Buy | Buy |
| Mar 17, 2026 | Guggenheim | Maintained | Buy | Buy |
| Mar 9, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 11, 2026 | Stifel | Initiated | — | Buy |
| Jan 7, 2026 | UBS | Initiated | — | Buy |
| Jan 7, 2026 | Piper Sandler | Initiated | — | Overweight |
| Dec 12, 2025 | Citigroup | Maintained | Buy | Buy |
| Dec 11, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Dec 11, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Dec 11, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 21, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Nov 18, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Nov 18, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 18, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 20, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 8, 2025 | Guggenheim | Initiated | — | Buy |
| Sep 3, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Aug 14, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 12, 2025 | Citigroup | Maintained | Buy | Buy |
| May 14, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| May 14, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Apr 28, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 28, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Mar 19, 2025 | Oppenheimer | Reiterated | Outperform | Outperform |
| Mar 19, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 11, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |